Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28069171 | 0.96 | S1PR5 (0.39) | S1PR5TSHRFABP3LMNAMEN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL28122918 | 0.91 | S1PR5 (0.36) | S1PR5TSHRFABP3LMNAMEN1 | |
| SCHEMBL3413314 | 0.80 | LTB4R (0.40) | LTB4RLTB4R2SMN1; SMN2 | |
| SCHEMBL8376596 | 0.77 | DRD2 (0.39) | LMNAMEN1KMT2AALDH1A1CYP1A2 | |
| Sulfuric Acid SCHEMBL31514469 | 0.76 | ALDH1A1 (0.38) | TSHRMEN1KMT2AALDH1A1TDP1 | |
| Sulfuric Acid SCHEMBL10339576 | 0.76 | ALDH1A1 (0.38) | TSHRMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL2292527 | 0.75 | ALOX5 (0.48) | MEN1KMT2AALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL17187689 | 0.74 | CYP2C19 (0.46) | TSHRLMNAKMT2AALDH1A1CYP2C19 | |
| SCHEMBL4571028 | 0.72 | MEN1 (0.49) | LMNAMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL11278093 | 0.71 | S1PR5 (0.47) | S1PR5TSHRLTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8535511-B2 | Methods for electrochemical analysis using matrix compositions with alkylphenazine quaternary salt and a nitrosoaniline | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-8008037-B2 | Matrix composition with alkylphenazine quaternary salt and a nitrosoaniline | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2011-08-30 | — | — | US | claimed |
| JP-2100699-A | — | — | None | — | — | JP | disclosed |
| EP-3131882-B1 | PHENAZINIUM MEDIATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2020-07-15 | — | — | EP | disclosed |
| CN-106164054-B | Phenazine mediators | 豪夫迈·罗氏有限公司 | 2019-05-07 | — | — | CN | disclosed |
| CN-108845132-A | Reagent material and related test element | 霍夫曼-拉罗奇有限公司 | 2018-11-20 | — | — | CN | disclosed |
| CN-108841913-A | Reagent material and related test element | 霍夫曼-拉罗奇有限公司 | 2018-11-20 | — | — | CN | disclosed |
| EP-2914735-B1 | REAGENT MATERIALS AND ASSOCIATED TEST ELEMENTS | ROCHE DIABETES CARE GMBH (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-9988358-B2 | Phenazinium mediators | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170226068-A1 | PHENAZINIUM MEDIATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-10 | — | — | US | disclosed |
| EP-3131882-A1 | PHENAZINIUM MEDIATORS | Roche Diagnostics GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| WO-2014068022-A1 | REAGENT MATERIALS AND ASSOCIATED TEST ELEMENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2014-05-08 | — | — | WO | disclosed |
| US-20140127728-A1 | REAGENT MATERIALS AND ASSOCIATED TEST ELEMENTS | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2265726-B1 | BIOSENSOR WITH IMPROVED ANALYTE SPECIFICITY | ROCHE DIAGNOSTICS GMBH (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-8535511-B2 | Methods for electrochemical analysis using matrix compositions with alkylphenazine quaternary salt and a nitrosoaniline | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8008037-B2 | Matrix composition with alkylphenazine quaternary salt and a nitrosoaniline | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2265726-A1 | BIOSENSOR WITH IMPROVED ANALYTE SPECIFICITY | Roche Diagnostics GmbH (DE) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009118157-A1 | BIOSENSOR WITH IMPROVED ANALYTE SPECIFICITY | ROCHE DIAGNOSTICS GMBH (DE) | 2009-10-01 | — | — | WO | disclosed |
| US-20090246808-A1 | BIOSENSOR WITH IMPROVED ANALYTE SPECIFICITY | ROCHE DIABETES CARE, INC. | 2009-10-01 | — | — | US | disclosed |
| JP-H02100699-A | MEASUREMENT OF ORGANISM SAMPLE | MITSUBISHI GAS CHEM CO INC | 1990-04-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226068-A1 | PHENAZINIUM MEDIATORS | IL5, TRPV5, TRPM5 | S1PR5 1279/4885TSHR 4408/4885FABP3 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.